Sterinova opens sterile injectables plant in Canada

A new facility focused on ready-to-use sterile injectables has come on the scene in Canada, having been built with help from public funds.

Sterinova has opened a $53.3 million ($70 million Canadian) facility in Saint-Hyacinthe in Quebec, having received more than $7 million in funds from public sources. The 67,000-sq-ft facility will make products in syringes and premix solutions containers. A Sterinova spokeswoman said its first product will be a syringe of the anticoagulant heparin sodium, which she said is the first prefilled syringe of that specific product in the market.

"Sterinova is one of the few pharmaceutical companies in the world to be entirely dedicated to the manufacture of ready-to-use injectable products,” Jean-Philippe Gentès, one of the company founders, said in a statement. “Its state of the art technology and its production capacity will make Sterinova an important Canadian player on international markets."

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The project received about $5.3 million ($7 million Canadian) from the Quebec Manufacturing Fund and another $1.5 million ($2 million Canadian) from the government of Quebec. The plant was designed with enough space so that its capacity can be doubled, the company said in its announcement. The plant has 55 workers, and another 50 are expected to be added as the company expands. Currently the plant is approved by Health Canada, the company said.

Some of the big players, like Sandoz and Sanofi, have sterile drug manufacturing in Canada, as well as some smaller operations, like Jubilant Life Sciences. Sterile injectables is a hot market right now and there has been considerable M&A action in that field in recent years as more drugmakers develop biologic drugs and contract manufacturers look to cash in on the trend. Last year, for example, Swedish CDMO Recipharm agreed to pay $105.2 million to buy a 74% stake in Indian sterile injectables CMO Nitin Lifesciences.

Related Articles:
Sandoz resumes production at Canada plant after accord reached with union
Jubilant says the FDA has cleared its Canada plant
Recipharm shelling out $105M for Indian sterile injectables CMO

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.